Microcap Ledger Bluejay Diagnostics, Inc. $BJDX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Acton, MA
- Fiscal year end
- December 31
- Shares outstanding
- 4,468,051 [10-Q 2026-08-12]
What the company doesAI summary of filing
Bluejay Diagnostics is a pre-revenue medical diagnostics company developing the Symphony platform, a rapid blood-based test system for critical care settings with an initial focus on sepsis. The company is currently in clinical trials with its first product candidate, the Symphony IL-6 test, which measures a biomarker to assess mortality risk in sepsis patients; it has not yet received FDA clearance and does not generate revenue. Bluejay plans to make money by selling analyzers (with financing options) and recurring revenue from single-use test cartridges, with goals to expand its test menu to other conditions. The company expects to need at least $20 million in additional capital by the end of fiscal year 2027 to pursue regulatory submission and commercialization. [10-K 2026-03-06]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$4.24M | −$3.09M | $9.60M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$6.85M | −$6.05M | $5.16M | [10-K 2026-03-06] |
| FY ended Dec 2024 | — | −$7.72M | −$7.82M | $4.30M | [10-K 2026-03-06] |
- Quarterly cash burn
- −$1.54M
- Cash runway Estimate
- ~18.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-21 | 554,012 | [10-K 2025-03-31] |
| 2025-04-28 | 1,494,167 | [10-K/A 2025-04-29] |
| 2025-05-12 | 1,494,182 | [10-Q 2025-05-13] |
| 2025-08-01 | 1,494,182 | [10-Q 2025-08-07] |
| 2025-11-06 | 1,814,133 | [10-Q 2025-11-07] |
| 2026-03-02 | 972,215 | [10-K 2026-03-06] |
| 2026-05-04 | 1,034,715 | [10-Q 2026-05-07] |
| 2026-08-07 | 4,468,051 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-06-17; declared effective 2026-06-26 [S-3 2026-06-17]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-17 | Dey Indranil | grant | 28,000 | — | [4 2026-08-18] |
| 2026-07-10 | Hrt Financial Lp | sell | 34,938 | $1.40 | [4 2026-07-13] |
| 2026-07-09 | Hrt Financial Lp | buy | 64,047 | $1.51 | [4 2026-07-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Regulation FD disclosure |
| 2026-09-08 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Regulation FD disclosure |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-22 | 8-K | Regulation FD disclosure |
| 2026-06-26 | 424B3 | Prospectus or prospectus supplement |
| 2026-06-17 | S-3 | Registration statement |
| 2026-06-09 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-08 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-06-05 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $BJDX
Email me when Bluejay Diagnostics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.